IDH1 and acute myeloid leukemia: A clinical trial combining azacitidine with ivosidenib in newly diagnosed IDH1-mutant AML reported that the estimated probability that a patient would remain event-free at 12 months was 37% in the ivosidenib-and-azacitidine group and 12% in the placebo-and-azacitidine group.